

| Corresponding author(s):   | Oliver Mühlemann |
|----------------------------|------------------|
| Last updated by author(s): | Jul 7, 2020      |

## **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

| $\sim$ |     |      |     |
|--------|-----|------|-----|
| St     | atı | ICT. | 100 |

| all st      | atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.   |
|-------------|---|
| Cor         | nfirmed   |
| $\boxtimes$ | The exact sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement   |
| $\boxtimes$ | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly   |
| $\boxtimes$ | The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.  |
|             | A description of all covariates tested  |
|             | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons   |
| $\boxtimes$ | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| $\boxtimes$ | For null hypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted Give $P$ values as exact values whenever suitable.  |
|             | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |
|             | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |
|             | Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated  |
|             | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.   |
|             | Corr  |

## Software and code

Policy information about availability of computer code

Data collection No software was used for data collection

Data analysis ImageJ 1.52p and Rotor-Gene 6200 version 2.3.1 software

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

## Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Ribo-Seq data used in Figure 5 has been deposited in the Gene Expression Ominibus (GEO) under accesion numbers:

GSM4256659 SK1\_M (L6)

GSM4256660 SK2\_M (L6) GSM4256661 SK3\_M (L6)

GSM4256665 SK1\_M (L7)

GSM4256666 SK2\_M (L7)

GSM4256667 SK3\_M (L7)

Each biological replicate (SK1-3) has been sequenced in two lanes (L6 and L7) and deposited individually. Total RNA sequencing data for UPF1 KD conditions that were used to compile a list of NMD-sensitive transcripts are deposited under accession numbers: GSM4407914, GSM4407915, GSM4407916. The data will be made public upon acceptance of the manuscript. Meanwhile, for review purpose only, the data can be accessed with the following token: ozyjskeknjidnsz

| =  |   |  |  |
|--|---|--|--|
| Field-spe  | ecitic re   | porting  |  |
| Please select the or   | ne below that i   | s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.   |  |
| ∑ Life sciences  |   | Behavioural & social sciences  |  |
| For a reference copy of t  | he document with  | all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>  |  |
| Life scier   | nces sti  | udy design   |  |
| All studies must dis   | close on these  | points even when the disclosure is negative.   |  |
| Sample size  | A total of minir  | num three biological measurements has been selected following common practice for molecular biology experiments.   |  |
| Data exclusions  | No data are exc   | cluded, for toeprint assays, one representative replicate is shown.  |  |
| Replication  | Three biological replicates were performed for all experiments performed in HeLa cell lines. In vitro translation experiments and toeprint assays were performed at least three times and were considered as valid when the same result was observed in all replicates with valid controls. All attempts at replication were successful |  |  |
| Randomization  | Not applicable. We did not perform experiments that require randomization.  |  |  |
| Blinding   | Not applicable.   | We did not perform experiments that require randomization.   |  |
| We require informatic system or method list  Materials & exp.  n/a Involved in th  Antibodies  Eukaryotic  Palaeontolo  Animals an | on from authors led is relevant to cerimental s e study cell lines ogy d other organisn earch participan  | n/a Involved in the study  ChIP-seq  Flow cytometry  MRI-based neuroimaging  |  |
| Antibodies used  |   | PF1 (Bethyl A300-038A, 1:1000), ABCE1 (Abcam, ab185548, 1:1000), beta-actin (Sigma Aldrich A5060, 1:2000), Rluc (Thermo sher PA5-32210, 1:600), Tyr-Tubulin (Sigma T9028, 1:5000). |  |
| Validation   |   | alidation of antibodies is done by western blot in the corresponding manufacturer's websites and for UPF1 and ABCE1 after RNA-mediated knockdowns in the present study.            |  |
| Eukaryotic c   | ell lines   |  |  |
| Policy information a   | about <u>cell lines</u>   |  |  |
| Cell line source(s)  | )   | HeLa (ATCC; CCL2), HeLa TCRβ PTC 68 (Hela tetR clone 9) was developed and validated in our lab (Eberle A et al., PLoS Biol. 6, e92 (2008).)  |  |
|  |   | HeLa TCRβ PTC 68 (Hela tetR clone 9) was authenticated by qPCR by readout of the TCRβ constructs (Eberle A et al., PLoS Biol. 6, e92 (2008).)                                      |  |
| Mycoplasma contamination  All cell lines were tested negative for Mycoplasma contamination   |   | All cell lines were tested negative for Mycoplasma contamination   |  |

Commonly misidentified lines (See ICLAC register)

No commonly misidentified cell lines were used in the study.

n | reporting summary